ST段抬高型心肌梗死药物洗脱支架植入后6个月与12个月双联抗血小板治疗(DAPT-STEMI):随机、多中心、非劣效性试验
DAPT-STEMI为前瞻性、随机、多中心、非劣效性试验,纳入18至85岁因STEMI行直接PCI并植入第二代佐他莫司洗脱支架的患者,首次PCI后6个月无事件者按1:1随机分为仅用阿司匹林单抗(SAPT)或继续双抗6个月(DAPT),随机后再随访18个月。共纳入1100例,870例随机(SAPT 432例 vs DAPT 438例)。随机后18个月主要复合终点(全因死亡、任何心肌梗死、任何血运重建、卒中、TIMI大出血)SAPT组4.8% vs DAPT组6.6%(HR 0.73,95%CI 0.41-1.27,P=0.26),非劣效成立(非劣效P=0.004),95%CI上限1.27小于预设非劣效界值1.66。结论为6个月DAPT非劣于12个月DAPT。
要点
- 首次PCI后6个月无事件的STEMI患者随机,SAPT组432例 vs DAPT组438例,随机后18个月主要复合终点4.8% vs 6.6%(HR 0.73,95%CI 0.41-1.27,P=0.26)。
- 非劣效成立:非劣效P=0.004,95%CI上限1.27小于预设非劣效界值1.66。
- 研究人群为18至85岁STEMI、直接PCI植入第二代佐他莫司洗脱支架、6个月时无事件者,随机时正在服用DAPT。
- 所有随机患者再随访18个月(即首次PCI后24个月),主要终点为随机后18个月的全因死亡、任何心肌梗死、任何血运重建、卒中、TIMI大出血复合终点。
- 试验注册号NCT01459627,纳入时间为2011年12月19日至2015年6月30日。
适用人群与场景
- 18至85岁STEMI患者,行直接PCI并植入第二代药物洗脱支架。
- 首次PCI后6个月无事件、且正在服用DAPT的患者在此时间点随机。
诊断标准与关键阈值
- 非劣效界值:预设HR上限1.66,实际95%CI上限1.27小于该界值,非劣效P=0.004。
处置流程与药物剂量
- 首次PCI后6个月无事件者按1:1随机至单抗(仅阿司匹林)或继续DAPT额外6个月,随机后再随访18个月。
研究设计与关键结果
- 前瞻性、随机、多中心、非劣效性试验,纳入1100例,870例随机(SAPT 432例 vs DAPT 438例)。
- 随机后18个月主要复合终点(全因死亡、任何心肌梗死、任何血运重建、卒中、TIMI大出血)SAPT组4.8% vs DAPT组6.6%(HR 0.73,95%CI 0.41-1.27,P=0.26)。
- 非劣效成立(非劣效P=0.004),95%CI上限1.27小于预设非劣效界值1.66。
证据类型、等级与局限
- 证据类型:前瞻性、随机、多中心、非劣效性试验(DAPT-STEMI,NCT01459627)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于首次PCI植入第二代佐他莫司洗脱支架后6个月无事件的STEMI患者,6个月DAPT在18个月复合终点上非劣于12个月DAPT,支持在此人群考虑6个月DAPT。
指南或共识出处
- DAPT-STEMI试验,ClinicalTrials.gov NCT01459627。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with event-free ST-elevation myocardial infarction (STEMI) results in a non-inferior clinical outcome versus DAPT for 12 months.
DESIGN: Prospective, randomised, multicentre, non-inferiority trial.
SETTING: Patients with STEMI treated with primary percutaneous coronary intervention (PCI) and second generation zotarolimus-eluting stent.
PARTICIPANTS: Patients with STEMI aged 18 to 85 that underwent a primary PCI with the implantation of second generation drug-eluting stents were enrolled in the trial. Patients that were event-free at six months after primary PCI were randomised at this time point.
INTERVENTIONS: Patients that were taking DAPT and were event-free at six months were randomised 1:1 to single antiplatelet therapy (SAPT) (ie, aspirin only) or to DAPT for an additional six months. All patients that were randomised were then followed for another 18 months (ie, 24 months after the primary PCI).
MAIN OUTCOME MEASURES: The primary endpoint was a composite of all cause mortality, any myocardial infarction, any revascularisation, stroke, and thrombolysis in myocardial infarction major bleeding at 18 months after randomisation.
RESULTS: A total of 1100 patients were enrolled in the trial between 19 December 2011 and 30 June 2015. 870 were randomised: 432 to SAPT versus 438 to DAPT. The primary endpoint occurred in 4.8% of patients receiving SAPT versus 6.6% of patients receiving DAPT (hazard ratio 0.73, 95% confidence interval 0.41 to 1.27, P=0.26). Non-inferiority was met (P=0.004 for non-inferiority), as the upper 95% confidence interval of 1.27 was smaller than the prespecified non-inferiority margin of 1.66.
CONCLUSIONS: DAPT to six months was non-inferior to DAPT for 12 months in patients with event-free STEMI at six months after primary PCI with second generation drug-eluting stents.
TRIAL REGISTRATION: Clinicaltrials.gov NCT01459627.
参考来源
- Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018. PMID: 30279197. doi:10.1136/bmj.k3793
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。